Ventricular fibrillation

1. KN-93 protects against ventricular fibrillation in rats.

   “These arrhythmias were suppressed by the reducing agent N-acetylcysteine (2 mM) and CaMKII inhibitor KN-93 (1 microM) but not by its inactive form (KN-92, 1 microM).”

   Animalsheart1 microM

   Increased susceptibility of aged hearts to ventricular fibrillation during oxidative stress

   American journal of physiology. Heart and circulatory physiology·18 Sep 2009

More on KN-93

1. Acetylcysteine protects against ventricular fibrillation in rats.

   “These arrhythmias were suppressed by the reducing agent N-acetylcysteine (2 mM) and CaMKII inhibitor KN-93 (1 microM)”

   Animalsheart2 mM

   Increased susceptibility of aged hearts to ventricular fibrillation during oxidative stress

   American journal of physiology. Heart and circulatory physiology·18 Sep 2009

More on Acetylcysteine

1. GLP-1 receptor agonists lower the risk of ventricular fibrillation in humans (RR 0.45 (95% CI: 0.38-0.53)).

   “ventricular fibrillation (RR, 0.45 (95% CI: 0.38-0.53), p<0.01)”

   Humansin obese patients aged ≥18 years1 year

   Association between Glucagon-like peptide-1 receptor agonists and risk of Arrhythmias: A Contemporary Real-World Analysis

   AHA Scientific Sessions 2025 abstract·3 Nov 2025

2. GLP-1 receptor agonists lower the risk of ventricular fibrillation in humans (RR 0.428, 95% CI: 0.243–0.754, p = 0.002).

   “patients receiving GLP/GIP therapy had lower risks of VFib (RR 0.428, 95% CI: 0.243–0.754, p = 0.002)”

   Humansin patients with cardiac amyloidosisbetween 90 and 365 days

   Glucagon Receptor Agonist Impact on Cardiac Amyloidosis. A Retrospective Propensity Matched Analysis

   AHA Scientific Sessions 2025 abstract·3 Nov 2025

More on GLP-1 receptor agonists